The Family Firm’s Biogen BIIB Stock Holding History

The Family Firm’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-62	Closed	-$14.4K	–	273
2024 Q2	$14.4K	Buy	+62	New	+$13.5K	﹤0.01%	621

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

The Family Firm's BIIB Position: Q3 2024 in Review

The Family Firm sold out of Biogen (BIIB) in Q3 2024, closing a stake of 62 shares — an estimated $14.4K sold.

The Family Firm first reported a position in BIIB in Q2 2024 and held it in 1 quarter. The position peaked at $14.4K in Q2 2024. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

The Family Firm reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
The Family Firm sold 62 Biogen shares in Q3 2024, an estimated $14.4K.
The Family Firm first reported a position in Biogen in Q2 2024 and held it in 1 quarter.
The Family Firm's Biogen position peaked at $14.4K in Q2 2024.
916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.